A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure
Por:
Moliner-Abos, C, Alvarez, DM, Rivas-Lasarte, M, Belarte, LC, Besora, JP, Sole-Gonzalez, E, Fluvia-Brugues, P, Zegri-Reiriz, I, Lopez, LL, Brossa, V, Pirla, MJ, Mesado, N, Mirabet, S, Roig, E, Alvarez-Garcia, J
Publicada:
18 feb 2021
Resumen:
Introduction Sacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slower than expected. Our objective was to develop a score predicting the super-response to SV in HF outpatients. Methods This is a retrospective analysis of 185 consecutive patients prescribed SV from two tertiary hospitals between September 2016 and February 2018. Super-responder was defined as a patient taking the drug and (i) without HF admissions, death, or heart transplant, and (ii) with a >= 50% reduction in NT-proBNP levels and/or an increase of >= 10 points in LVEF in a 12-month follow-up period after starting SV. Clinical, echocardiographic, ECG, and biochemical variables were used in a logistic regression analysis to construct a score for super-response to SV which was internally validated using bootstrap method. Results Out of 185 patients, 65 (35%) fulfilled the super-responder criteria. Predictors for super-response to SV were absence of both previous aldosterone antagonist and diuretic treatment, NYHA I-II class, female gender, previous 1-year HF admission, and sinus rhythm. An integrating score distinguished a low- (<25%), intermediate- (similar to 46%), and high-probability (>80%) for 1-year super-response to SV. The AUC for the model was 0.72 (95%CI: 0.64-0.80), remaining consistent after internal validation. Conclusion One-third of our patients presented a super-response to SV. We propose an easy-to-calculate score to predict super-response to SV after 1-year initiation based on variables that are currently assessed in clinical practice.
Filiaciones:
Moliner-Abos, C:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Alvarez, DM:
Hosp del Mar, Cardiol Dept, Barcelona, Spain
Rivas-Lasarte, M:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Belarte, LC:
Hosp del Mar, Cardiol Dept, Barcelona, Spain
Besora, JP:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Sole-Gonzalez, E:
Hosp del Mar, Cardiol Dept, Barcelona, Spain
Fluvia-Brugues, P:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Zegri-Reiriz, I:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Lopez, LL:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Brossa, V:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Pirla, MJ:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Mesado, N:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Mirabet, S:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Roig, E:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Alvarez-Garcia, J:
Univ Autonoma Barcelona, CIBERCV, Hosp Santa Creu & St Pau, Cardiol Dept,IIB SantPau, Barcelona, Spain
Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY 10029 USA
Green Published, gold
|